Study Group: Prescribers of Aralast NP (US)(?)
Council Members in this Study Group: 17
Request a survey with this Study Group
Leading Experts in this Study Group
Robert Aris, MD
Associate Professor of Medicine
University of North Carolina Chapel Hill - CC
Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic...
President
PSS Clinical Research
Warren Botnick, MD, FCCP, DABSM, is a Partner at Pulmonary and Sleep Specialists in Decatur, Georgia, since March 2003. He is Director of Critical Care Unit and Chief of Medicine at DeKalb Medical Center, Medical Director of Southern Sleep Technologies, and Co-Director of two sleep disorders centers...
Associate Professor of Medicine
University Of Rochester Medical Center
Michael Kallay, MD, is Associate Professor of Medicine at the University of Rochester. His expertise is in asthma, exercise physiology and COPD, and interstitial lung diseases and his research interest in the management of interstitial lung diseases. Dr. Kallay has been a principal investigator in over...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Oral Treprostinil: An effective medicine hiding in a study with a challenging design?
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients. This is important because the definition of functional class II is that a patient has a sight...
This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...
Eicosanoids appear promising in the treatment of such airways diseases as COPD and asthma, which affect millions worldwide. Any alternative to current anti-inflammatory therapy, which consists almost entirely of forms of corticosteroids, would almost certainly be welcomed and adopted in widespread...
Cephalosporins have been standard therapy for pneumonia for many years, but to date this class of drug has been ineffective against MRSA. Ceftobiprole appears to represent a breakthrough in this regard. I would expect the drug to be well tolerated and, for the most part, to cause few major...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Laboratory, Independent
- Non-Academic Community Hospital or Clinic
- Private/For-Profit Healthcare Research Entity
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Medical Director
- President
- Partner